TA201

Asthma (in children) - omalizumab (TA201) (replaced by TA278)

  • Technology appraisals TA201
  • Issued: October 2010
    • Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11

      This guidance has been replaced by TA278 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)

      This guidance is about when omalizumab should be used to treat children aged 6 to 11 years with severe persistent allergic asthma in the NHS in England and Wales.

      Asthma is a common condition that causes the airways to become narrower. Children with asthma have breathing difficulties, wheezing, coughing and feel a tightness in their chest. These symptoms get worse when they have an 'asthma attack'. Allergic asthma is caused by an allergy (for example, an allergy to pollen or dust mites). Children with severe persistent allergic asthma have frequent asthma attacks and often wake during the night because of their asthma.

      What has NICE said?

      NICE does not recommend omalizumab for children aged 6 to 11 years with severe persistent allergic asthma.

      Why has NICE said this?

      NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. Omalizumab does not provide enough benefit to children aged 6 to 11 years to justify its high cost.

      This page was last updated: 19 April 2013

    • Guidance formats

      Query

Implementation tools and resources

  • None available

See this guidance in practice

Patient

The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.

Quick Reference Guide

The quick reference guide presents recommendations for health professionals

NICE Guidance

The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.

Full Guidance

The published full clinical guidance for specialists with background, evidence, recommendations and methods used.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.